Crinetics director granted RSUs and stock options

Crinetics Pharmaceuticals director Stephanie Okey received new equity awards as board compensation.

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Stephanie Okey received new equity awards as board compensation. She was granted 5,925 restricted stock units representing future common shares and a stock option for 9,730 shares at an exercise price of $35.87 per share. The restricted stock units and option vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued board service. Following the grant, she holds 12,325 shares of common stock directly.

Insights

Equity compensation analyst

Routine director equity grants add exposure but are not a trading signal.

Crinetics Pharmaceuticals granted director Stephanie Okey 5,925 restricted stock units and options on 9,730 shares at an exercise price of $35.87. These awards are standard board compensation rather than open-market buying.

The awards vest in full on the earlier of the first grant anniversary or the next annual stockholder meeting, subject to continued board service. Because they are compensation grants with no cash outlay and no immediate sale, they carry limited information about short-term expectations.

After the grant, Okey directly holds 12,325 common shares and has the newly awarded options outstanding until their expiration in 2036. Future company filings may detail any exercises or sales if and when they occur.

Insider Trade Summary

Grant/Award: 15,655 shares

Grant/Award 2 txns

Insider Okey Stephanie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,730	$0.00	$0.00
Grant/Award	Common Stock	5,925	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,730 contracts (Direct); Common Stock — 12,325 shares (Direct)

Footnotes (2)

1. F1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
2. F2. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Key Figures

Restricted stock units granted: 5,925 units Stock options granted: 9,730 options Option exercise price: $35.87 per share +3 more

6 metrics

Restricted stock units granted 5,925 units Equity award to director on June 18, 2026

Stock options granted 9,730 options Right to buy common stock granted June 18, 2026

Option exercise price $35.87 per share Strike price for 9,730-share option grant

Option expiration June 18, 2036 Expiration date for stock option grant

Shares owned after grant 12,325 shares Director’s direct common stock holdings post-transaction

RSU vesting trigger 1 year or next annual meeting Earlier of grant anniversary or next stockholder meeting

Key Terms

restricted stock units, stock option, exercise price, vesting, +1 more

5 terms

restricted stock units financial

"involves the receipt of restricted stock units, which represent the right to receive shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"The stock option shall vest and become exercisable on the earlier of"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"Stock Option (Right to Buy) with a conversion or exercise price of 35.8700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"with 100% vesting on the earlier of (a) the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Stephanie Okey receive from Crinetics Pharmaceuticals (CRNX)?

Stephanie Okey received 5,925 restricted stock units and a stock option for 9,730 shares of Crinetics Pharmaceuticals common stock at an exercise price of $35.87. These awards are part of her compensation for serving on the company’s board of directors.

How do the new restricted stock units for CRNX director Stephanie Okey vest?

The 5,925 restricted stock units vest 100% on the earlier of the first anniversary of the grant date or the next annual meeting of Crinetics stockholders. Vesting is conditioned on Stephanie Okey continuing to serve on the company’s board through that vesting date.

What are the key terms of Stephanie Okey’s new Crinetics stock options?

Stephanie Okey received stock options for 9,730 shares of Crinetics common stock with a $35.87 exercise price. The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting and expire in 2036 if not exercised.

How many Crinetics (CRNX) shares does Stephanie Okey hold after this Form 4 transaction?

After the reported grant, Stephanie Okey directly holds 12,325 shares of Crinetics common stock. This figure reflects her ownership following receipt of 5,925 restricted stock units, which represent the right to receive additional shares when they vest under the award terms.

Is Stephanie Okey’s Form 4 transaction in CRNX an open-market purchase or sale?

The Form 4 shows compensation-related equity grants, not open-market trades. Stephanie Okey acquired 5,925 restricted stock units and options for 9,730 shares at $35.87 as board compensation, with no reported open-market buying or selling of Crinetics common stock in this filing.

When will Stephanie Okey’s new Crinetics equity awards fully vest?

Both the 5,925 restricted stock units and the 9,730-share stock option vest fully on the earlier of the first anniversary of the grant date or the next annual meeting of Crinetics stockholders, assuming Stephanie Okey continues serving on the board until that vesting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okey Stephanie

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		5,925	A	$0(1)	12,325	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.87	06/18/2026		A		9,730		(2)	06/18/2036	Common Stock	9,730	$0	9,730	D

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

2. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)